Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P.

Lancet Haematol. 2019 Jul 16. pii: S2352-3026(19)30113-9. doi: 10.1016/S2352-3026(19)30113-9. [Epub ahead of print]

PMID:
31324600
2.

Diagnosis and immediate treatment of acquired von Willebrand syndrome revealed by recurrent cerebral hemorrhage.

Pineau-Vincent F, Legout A, Besancon-Bergelin A, Alani M, Laribi K, Lemaire P.

Transfus Clin Biol. 2019 Jun 12. pii: S1246-7820(19)30066-7. doi: 10.1016/j.tracli.2019.05.006. [Epub ahead of print]

PMID:
31262628
3.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 May 22. doi: 10.1038/s41375-019-0431-y. [Epub ahead of print]

PMID:
31118465
4.

Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group.

Nudel M, Baran-Marszak F, Bossard JB, Dubois R, Dapvril H, Dupuis J, Laribi K, Bay JO, Tomowiak C, Dreyfus B, Lepretre S, Demarquette H, Wallyn F, Wemeau L, Wemeau M, Poulain S, Morschhauser F, Cymbalista F, Herbaux C.

Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15966. [Epub ahead of print] No abstract available.

PMID:
31115898
5.

New insights in the treatment of patients with solitary bone plasmacytoma.

Mheidly K, Lamy De La Chapelle T, Hunault M, Benboubker L, Benchalal M, Moreau P, Baugier de Materre A, Decaux O, Laribi K.

Leuk Lymphoma. 2019 Apr 25:1-4. doi: 10.1080/10428194.2019.1605067. [Epub ahead of print] No abstract available.

PMID:
31020888
6.

Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.

Laribi K, Bolle D, Alani M, Ghnaya H, Besançon A, Farhi J, Mheidly K, Denizon N, Baugier de Materre A.

Cancer Med. 2019 May;8(5):2188-2195. doi: 10.1002/cam4.2121. Epub 2019 Apr 16.

7.

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel.

Denis D, Beneton N, Laribi K, Maillard H.

Cancer Manag Res. 2019 Mar 20;11:2241-2251. doi: 10.2147/CMAR.S138661. eCollection 2019. Review.

8.

Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.

Laribi K, Badinand D, Janoray P, Benabed K, Mouysset JL, Fabre E, Monchecourt F, Diab R.

Support Care Cancer. 2019 Mar 14. doi: 10.1007/s00520-019-04725-0. [Epub ahead of print]

PMID:
30874925
9.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

10.

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.

Br J Haematol. 2019 Jul;186(1):146-149. doi: 10.1111/bjh.15718. Epub 2018 Dec 12. No abstract available.

PMID:
30548257
11.

Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.

Wesner N, Drevon L, Guedon A, Fraison JB, Terrier B, Trad S, Kahn JE, Aouba A, Gillard J, Ponsoye M, Hanslik T, Gourguechon C, Liozon E, Laribi K, Rossignol J, Hermine O, Seksik P, Adès L, Carrat F, Fenaux P, Mekinian A, Fain O; On behalf GFM and MINHEMON (French Network of dysimmune disorders associated with hemopathies).

Leuk Lymphoma. 2019 Jul;60(7):1782-1788. doi: 10.1080/10428194.2018.1542152. Epub 2018 Nov 20.

PMID:
30457024
12.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

13.

Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.

Wesner N, Drevon L, Guedon A, Fraison JB, Trad S, Kahn JE, Aouba A, Gillard J, Ponsoye M, Hanslik T, Gourguechon C, Liozon E, Laribi K, Rossignol J, Hermine O, Adès L, Carrat F, Fenaux P, Mekinian A, Fain O; GFM, MINHEMON (French Network of Dysimmune Disorders Associated to Hemopathies).

Eur J Haematol. 2019 Jan;102(1):63-69. doi: 10.1111/ejh.13174. Epub 2018 Nov 14.

PMID:
30218579
14.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.

PMID:
30117149
15.

Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.

Farhi J, Laribi K, Orvain C, Hamel JF, Mercier M, Sutra Del Galy A, Clavert A, Rousselet MC, Tanguy-Schmidt A, Hunault-Berger M, Moles-Moreau MP.

Ann Hematol. 2018 Dec;97(12):2391-2401. doi: 10.1007/s00277-018-3468-5. Epub 2018 Aug 8.

PMID:
30091022
16.

Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis.

Debus J, Lemaire P, Alani M, Farhi J, Rose J, Cussac V, Defasque S, Denizon N, Ghnaya H, Besançon-Bergelin A, Laribi K, Pineau-Vincent F.

Ann Biol Clin (Paris). 2018 Aug 1;76(4):451-457. doi: 10.1684/abc.2018.1357.

PMID:
30078781
17.

Shwachman-Diamond syndrome: a case report.

Kaabar M, Lemaire P, Cussac V, Besancon A, Martin-Coignard D, Fenneteau O, Laribi K, Pineau-Vincent F.

Ann Biol Clin (Paris). 2018 Aug 1;76(4):435-438. doi: 10.1684/abc.2018.1358.

PMID:
30078780
18.

Chronic lymphocytic leukemia with t(14 ;18) and trisomy 12: a case report.

Le Guyader M, Coude M, Laribi K, Besançon A, Ghnaya H, Denizon N, Defasque S, Pineau-Vincent F, Kaabar M, Lemaire P.

Ann Biol Clin (Paris). 2018 Aug 1;76(4):445-450. doi: 10.1684/abc.2018.1353.

PMID:
29905151
19.

Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine.

Laribi K, Bolle D, Alani M, Ghnaya H, Le Bourdelles S, Besançon A, Farhi J, Denizon N, Baugier de Materre A.

Exp Hematol. 2018 Sep;65:34-37. doi: 10.1016/j.exphem.2018.05.006. Epub 2018 Jun 5.

PMID:
29883686
20.

IgM k multiple myeloma with monoclonal surface immunoglobulin expression.

Laribi K, Alani M, Lemaire P.

Int J Hematol. 2018 Jul;108(1):3-4. doi: 10.1007/s12185-018-2467-6. Epub 2018 May 19. No abstract available.

PMID:
29779080
21.

Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.

Laribi K, Alani M, Truong C, de Materre AB.

Recent Pat Anticancer Drug Discov. 2018;13(3):308-340. doi: 10.2174/1574892813666180517102801. Review.

PMID:
29769011
22.

Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.

Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S.

Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13088. [Epub ahead of print]

PMID:
29719933
23.

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.

Laribi K, Alani M, Truong C, Baugier de Materre A.

Oncologist. 2018 Sep;23(9):1039-1053. doi: 10.1634/theoncologist.2017-0524. Epub 2018 Apr 19. Review.

PMID:
29674443
24.

Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.

Denizon N, Baugier de Materre A, Alani M, Ghnaya H, Farhi J, Besançon A, Laribi K.

Leuk Lymphoma. 2018 Nov;59(11):2711-2714. doi: 10.1080/10428194.2018.1452214. Epub 2018 Mar 21. No abstract available.

PMID:
29561205
25.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group.

Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1.

26.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.

Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

PMID:
29429912
27.

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V.

Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1.

28.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
29.

Advances in the understanding and management of T-cell prolymphocytic leukemia.

Laribi K, Lemaire P, Sandrini J, Baugier de Materre A.

Oncotarget. 2017 Nov 1;8(61):104664-104686. doi: 10.18632/oncotarget.22272. eCollection 2017 Nov 28. Review.

30.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

31.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

32.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Am J Hematol. 2018 Jan;93(1):E24-E27. doi: 10.1002/ajh.24951. Epub 2017 Nov 17. No abstract available.

33.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.

J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.

34.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R.

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. No abstract available.

35.

IgD κ multiple myeloma and myelodysplastic syndrome.

Laribi K, Lemaire P.

Blood. 2017 Apr 13;129(15):2203. doi: 10.1182/blood-2016-09-738120. No abstract available.

36.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8.

PMID:
27783363
37.

R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.

Laribi K, Denizon N, Bolle D, Truong C, Besançon A, Sandrini J, Anghel A, Farhi J, Ghnaya H, Baugier de Materre A.

Ann Hematol. 2016 Oct;95(10):1705-14. doi: 10.1007/s00277-016-2768-x. Epub 2016 Aug 3.

PMID:
27485454
38.

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.

Laribi K, Tempescul A, Ghnaya H, Denizon N, Besançon A, Anghel A, Farhi J, Truong C, Lemaire P, Poulain S, Bolle D, Ianotto JC, Baugier de Materre A.

Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.

PMID:
27443419
39.

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A.

Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.

40.

Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.

Laribi K, Denizon N, Besançon A, Farhi J, Lemaire P, Sandrini J, Truong C, Ghnaya H, Baugier de Materre A.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1357-1367. doi: 10.1016/j.bbmt.2016.03.022. Epub 2016 Mar 26. Review.

41.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M.

Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21.

42.

Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.

Laribi K, Bolle D, Ghnaya H, Sandu A, Besançon A, Denizon N, Truong C, Pineau-Vincent F, de Materre AB.

Ann Hematol. 2016 Apr;95(5):765-9. doi: 10.1007/s00277-016-2605-2. Epub 2016 Feb 9.

PMID:
26858026
43.

Quadri-lineage disease involving nodal B-cell marginal zone lymphoma, high-grade B-cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia.

Laribi K, Ghnaya H, Mention PJ, Rousset H, Baugier de Materre A, Pineau-Vincent F, Truong C, Bolle D.

Clin Case Rep. 2015 Nov 13;4(1):39-42. doi: 10.1002/ccr3.393. eCollection 2016 Jan.

44.

[Blastic plasmacytoid dendritic cell neoplasm: two case reports].

Kaabar M, Lemaire P, Laribi K, Sandrini J, Pineau-Vincent F.

Ann Biol Clin (Paris). 2015 Nov-Dec;73(6):733-6. doi: 10.1684/abc.2015.1094. French.

45.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

46.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
47.

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R.

Support Care Cancer. 2016 Jan;24(1):67-75. doi: 10.1007/s00520-015-2728-3. Epub 2015 Apr 29.

PMID:
25921449
48.

Meningeal involvement in multiple myeloma.

Laribi K, Mellerio C, Baugier A, Ghnaya H, Denizon N, Besançon A, Laly M, Jadeau C.

Clin Case Rep. 2015 Feb;3(2):84-7. doi: 10.1002/ccr3.160. Epub 2014 Nov 17.

49.

Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine.

Laribi K, Denizon N, Ghnaya H, Atlassi M, Besançon A, Pineau-Vincent F, Gaulard P, Petrella T.

Eur J Haematol. 2014 Jul;93(1):81-5. doi: 10.1111/ejh.12294. Epub 2014 Apr 1.

PMID:
24571716
50.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ.

Br J Haematol. 2013 Sep;162(6):783-91. doi: 10.1111/bjh.12459. Epub 2013 Jul 13.

PMID:
23848933

Supplemental Content

Loading ...
Support Center